Moderna Sales Get Lift From Early Nod

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...
Shares of Moderna, Inc. ($MRNA), among the frontrunners in mRNA vaccine technology, fell on Tuesday, bucking the broader market strength. The weakness came after Bloomberg reported, citing a person ...
In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...